Erytech To Conduct Pancreatic Cancer Trial

Erytech Pharma has launched a Phase II study of Eryasp in pancreatic cancer. Erytech completed a Phase I study in late-stage pancreas cancer, confirming  tolerability, and will continue the development in solid tumors by performing a Phase II study in second line pancreas cancer. In a study of about 100 patients, Eryasp in addition to the best standard of care will be compared to the best standard of care alone in a 2:1 randomization.

Thanks to an exclusive license from the National Institutes of Health (NIH) in the U.S., Erytech has a proprietary companion test allowing to identify the potential responders to treatment with asparaginase, with the plan of offering personalized treatment.

Patient enrollment is expected to start in 2Q14. Eryasp already holds orphan drug designation for the treatment of pancreas cancer in Europe and the U.S. Erysap is currently completing a Phase III trial in Acute Lymphoblastic Leukemia (ALL) and is in a Phase IIb trial in Acute Myeloid Leukemia (AML). The product has received FDA clearance to start clinical development in ALL in the U.S.